Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kanta Horie

Showing results (41-50 of 60) with videos related to

Pageof 6
Sort By:
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 24, 2025
BiomarkersCarling G Robinson, Alexa Pichet Binette, Kanta Horie, et al.
The Lancet. Neurology|March 21, 2026
Integration of plasma eMTBR-tau243 and p-tau217 in the diagnosis and stratification of Alzheimer's disease: a prospective cohort studyNiklas Mattsson-Carlgren, Sebastian Palmqvist, Kanta Horie, et al.
Cell Stem Cell|June 6, 2022
Recapitulation of endogenous 4R tau expression and formation of insoluble tau in directly reprogrammed human neuronsLucia S Capano, Chihiro Sato, Elena Ficulle, et al.
Acta Neuropathologica Communications|February 6, 2020
Pre-clinical characterisation of E2814, a high-affinity antibody targeting the microtubule-binding repeat domain of tau for passive immunotherapy in Alzheimer's diseaseMalcolm Roberts, Ioanna Sevastou, Yoichi Imaizumi, et al.
Nature Aging|April 28, 2023
CSF tau phosphorylation occupancies at T217 and T205 represent improved biomarkers of amyloid and tau pathology in Alzheimer's diseaseNicolas R Barthélemy, Benjamin Saef, Yan Li, et al.
JAMA Neurology|May 26, 2026
Plasma eMTBR-tau243 and %p-tau217 for Biological Staging of Alzheimer DiseaseGemma Salvadó, Kanta Horie, Nicolas R Barthélemy, et al.
Alzheimer'S Research & Therapy|April 10, 2026
Etalanetug (E2814) in dominantly inherited Alzheimer's disease: an open-label phase 1b/2 study to assess safety and target engagement in participants with mild to moderate cognitive impairmentErica Andreozzi, Takuya Yagi, Kristin Wildsmith, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 26, 2026
Tau-PET and CSF MTBR-tau243 comparisons validate increased tau aggregation in femalesCarling G Robinson, Alexa Pichet Binette, Kanta Horie, et al.
Nature Aging|March 22, 2024
Disease staging of Alzheimer's disease using a CSF-based biomarker modelGemma Salvadó, Kanta Horie, Nicolas R Barthélemy, et al.
Medrxiv : the Preprint Server for Health Sciences|July 28, 2023
Novel CSF tau biomarkers can be used for disease staging of sporadic Alzheimer's diseaseGemma Salvadó, Kanta Horie, Nicolas R Barthélemy, et al.
Pageof 6

Showing results (41-50 of 60) with videos related to

Sort By:
Pageof 6
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 24, 2025
BiomarkersCarling G Robinson, Alexa Pichet Binette, Kanta Horie, et al.
The Lancet. Neurology|March 21, 2026
Integration of plasma eMTBR-tau243 and p-tau217 in the diagnosis and stratification of Alzheimer's disease: a prospective cohort studyNiklas Mattsson-Carlgren, Sebastian Palmqvist, Kanta Horie, et al.
Cell Stem Cell|June 6, 2022
Recapitulation of endogenous 4R tau expression and formation of insoluble tau in directly reprogrammed human neuronsLucia S Capano, Chihiro Sato, Elena Ficulle, et al.
Acta Neuropathologica Communications|February 6, 2020
Pre-clinical characterisation of E2814, a high-affinity antibody targeting the microtubule-binding repeat domain of tau for passive immunotherapy in Alzheimer's diseaseMalcolm Roberts, Ioanna Sevastou, Yoichi Imaizumi, et al.
Nature Aging|April 28, 2023
CSF tau phosphorylation occupancies at T217 and T205 represent improved biomarkers of amyloid and tau pathology in Alzheimer's diseaseNicolas R Barthélemy, Benjamin Saef, Yan Li, et al.
JAMA Neurology|May 26, 2026
Plasma eMTBR-tau243 and %p-tau217 for Biological Staging of Alzheimer DiseaseGemma Salvadó, Kanta Horie, Nicolas R Barthélemy, et al.
Alzheimer'S Research & Therapy|April 10, 2026
Etalanetug (E2814) in dominantly inherited Alzheimer's disease: an open-label phase 1b/2 study to assess safety and target engagement in participants with mild to moderate cognitive impairmentErica Andreozzi, Takuya Yagi, Kristin Wildsmith, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 26, 2026
Tau-PET and CSF MTBR-tau243 comparisons validate increased tau aggregation in femalesCarling G Robinson, Alexa Pichet Binette, Kanta Horie, et al.
Nature Aging|March 22, 2024
Disease staging of Alzheimer's disease using a CSF-based biomarker modelGemma Salvadó, Kanta Horie, Nicolas R Barthélemy, et al.
Medrxiv : the Preprint Server for Health Sciences|July 28, 2023
Novel CSF tau biomarkers can be used for disease staging of sporadic Alzheimer's diseaseGemma Salvadó, Kanta Horie, Nicolas R Barthélemy, et al.
Pageof 6